Literature DB >> 24286018

Unique Pattern of Overexpression of Raf-1 Kinase Inhibitory Protein in Its Inactivated Phosphorylated Form in Human Multiple Myeloma.

Stavroula Baritaki1, Sara Huerta-Yepez, Ma da Lourdas Cabrava-Haimandez, Marialuisa Sensi, Silvana Canevari, Massimo Libra, Manuel Penichet, Haiming Chen, James R Berenson, Benjamin Bonavida.   

Abstract

Multiple myeloma (MM) is the second most common hematological and incurable malignancy of plasma cells with low proliferative activity in the bone marrow. MM patients initially respond to conventional therapy, however, many develop resistance and recurrences occur. We have identified RKIP as a novel gene product that is differentially overexpressed in MM cell lines and MM tissues compared to other studied tumors and normal bone marrow. This overexpression consisted, in large part, of a phosphorylated inactive form of RKIP at Ser153 (p-Ser153 RKIP). In contrast to RKIP, p-Ser153 RKIP lacks its ability to inhibit the MAPK signaling pathway. The overexpression of p-Ser153 RKIP in MM cell lines and MM tissues was further validated in a mouse model carrying a human MM xenograft, namely, LAGλ-1B. Bioinformatic analyses from databases support the presence of increased RKIP mRNA expression in MM compared to normal plasma cells. In these databases, high RKIP levels in MM are also correlated with the nonhyperdiploid status and the presence of IgH translocations, parameters that generally display more aggressive clinical features and shorter patients' survival irrespective of the treatment. Since RKIP expression regulates both the NF-κB and MAPK survival pathways, the overexpression of "inactive" p-Ser153 RKIP in MM might contribute positively to the overall cell survival/antiapoptotic phenotype and drug resistance of MM through the constitutive activation of survival pathways and downstream the transcription of anti-apoptotic gene products. The overexpression of RKIP and p-Ser153 RKIP in MM is the first demonstration in the literature, since in most tumor tissues the expression of RKIP is very low and the expression of p-Ser153 RKIP is much lower. The relationship between the levels of active RKIP and inactive p-Ser153 RKIP in MM may be of prognostic significance, and the regulation of RKIP activity may be a target for therapeutic intervention.

Entities:  

Keywords:  NF-κB; Raf-1 kinase inhibitor protein (RKIP); apoptosis; multiple myeloma

Year:  2011        PMID: 24286018      PMCID: PMC3839863          DOI: 10.1615/ForumImmunDisTher.v2.i2.90

Source DB:  PubMed          Journal:  For Immunopathol Dis Therap        ISSN: 2151-8017


  36 in total

1.  Snail is a repressor of RKIP transcription in metastatic prostate cancer cells.

Authors:  S Beach; H Tang; S Park; A S Dhillon; E T Keller; W Kolch; K C Yeung
Journal:  Oncogene       Date:  2007-10-22       Impact factor: 9.867

2.  LAGlambda-1: a clinically relevant drug resistant human multiple myeloma tumor murine model that enables rapid evaluation of treatments for multiple myeloma.

Authors:  Richard A Campbell; Steven J Manyak; Honghao H Yang; Nelida N Sjak-Shie; Haiming Chen; Dorina Gui; Laura Popoviciu; Cathy Wang; Melinda Gordon; Shen Pang; Benjamin Bonavida; Jonathan Said; James R Berenson
Journal:  Int J Oncol       Date:  2006-06       Impact factor: 5.650

3.  Raf kinase inhibitor protein interacts with NF-kappaB-inducing kinase and TAK1 and inhibits NF-kappaB activation.

Authors:  K C Yeung; D W Rose; A S Dhillon; D Yaros; M Gustafsson; D Chatterjee; B McFerran; J Wyche; W Kolch; J M Sedivy
Journal:  Mol Cell Biol       Date:  2001-11       Impact factor: 4.272

Review 4.  Treatment of relapsed/refractory multiple myeloma.

Authors:  Efstathios Kastritis; Antonio Palumbo; Meletios A Dimopoulos
Journal:  Semin Hematol       Date:  2009-04       Impact factor: 3.851

Review 5.  Role of transforming growth factor-beta in hematologic malignancies.

Authors:  Mei Dong; Gerard C Blobe
Journal:  Blood       Date:  2006-02-16       Impact factor: 22.113

6.  Pivotal roles of snail inhibition and RKIP induction by the proteasome inhibitor NPI-0052 in tumor cell chemoimmunosensitization.

Authors:  Stavroula Baritaki; Kam Yeung; Michael Palladino; James Berenson; Benjamin Bonavida
Journal:  Cancer Res       Date:  2009-10-20       Impact factor: 12.701

Review 7.  Multiple myeloma.

Authors:  Robert A Kyle; S Vincent Rajkumar
Journal:  Blood       Date:  2008-03-15       Impact factor: 22.113

8.  Effects of raf kinase inhibitor protein expression on suppression of prostate cancer metastasis.

Authors:  Zheng Fu; Peter C Smith; Lizhi Zhang; Mark A Rubin; Rodney L Dunn; Zhi Yao; Evan T Keller
Journal:  J Natl Cancer Inst       Date:  2003-06-18       Impact factor: 13.506

Review 9.  International Myeloma Working Group molecular classification of multiple myeloma: spotlight review.

Authors:  R Fonseca; P L Bergsagel; J Drach; J Shaughnessy; N Gutierrez; A K Stewart; G Morgan; B Van Ness; M Chesi; S Minvielle; A Neri; B Barlogie; W M Kuehl; P Liebisch; F Davies; S Chen-Kiang; B G M Durie; R Carrasco; Orhan Sezer; Tony Reiman; Linda Pilarski; H Avet-Loiseau
Journal:  Leukemia       Date:  2009-10-01       Impact factor: 11.528

Review 10.  Bone disease in myeloma.

Authors:  J R Berenson
Journal:  Curr Treat Options Oncol       Date:  2001-06
View more
  10 in total

1.  Prognostic value of phosphorylated Raf kinase inhibitory protein at serine 153 and its predictive effect on the clinical response to radiotherapy in nasopharyngeal carcinoma.

Authors:  Siwei Li; Taowen Liu; Wenfa Mo; Qiaoyan Hou; Yingqiong Zhou; Meilian Liu; Zhoukai He; Zhengchun Liu; Qiuqiu Chen; Hua Wang; Xiang Guo; Weixiong Xia; Musheng Zeng; Haiyun Zhao
Journal:  Radiat Oncol       Date:  2016-09-20       Impact factor: 3.481

Review 2.  Overexpression of RKIP and its cross-talk with several regulatory gene products in multiple myeloma.

Authors:  Anna Shvartsur; Kevin B Givechian; Hermes Garban; Benjamin Bonavida
Journal:  J Exp Clin Cancer Res       Date:  2017-05-05

Review 3.  Current Status of Raf Kinase Inhibitor Protein (RKIP) in Lung Cancer: Behind RTK Signaling.

Authors:  Ana Raquel-Cunha; Diana Cardoso-Carneiro; Rui M Reis; Olga Martinho
Journal:  Cells       Date:  2019-05-10       Impact factor: 6.600

Review 4.  Harnessing RKIP to Combat Heart Disease and Cancer.

Authors:  Kristina Lorenz; Marsha Rich Rosner
Journal:  Cancers (Basel)       Date:  2022-02-09       Impact factor: 6.575

Review 5.  The Role of RKIP in the Regulation of EMT in the Tumor Microenvironment.

Authors:  Hannah Cessna; Stavroula Baritaki; Apostolos Zaravinos; Benjamin Bonavida
Journal:  Cancers (Basel)       Date:  2022-09-22       Impact factor: 6.575

Review 6.  Targeting Raf Kinase Inhibitory Protein Regulation and Function.

Authors:  Ali Ekrem Yesilkanal; Marsha Rich Rosner
Journal:  Cancers (Basel)       Date:  2018-09-04       Impact factor: 6.639

Review 7.  RKIP: A Key Regulator in Tumor Metastasis Initiation and Resistance to Apoptosis: Therapeutic Targeting and Impact.

Authors:  Apostolos Zaravinos; Benjamin Bonavida; Ekaterini Chatzaki; Stavroula Baritaki
Journal:  Cancers (Basel)       Date:  2018-08-24       Impact factor: 6.639

8.  Up-regulation of microRNA-497 inhibits the proliferation, migration and invasion but increases the apoptosis of multiple myeloma cells through the MAPK/ERK signaling pathway by targeting Raf-1.

Authors:  Cheng-Yu Ye; Cui-Ping Zheng; Wei-Wei Ying; Shan-Shan Weng
Journal:  Cell Cycle       Date:  2018-12-11       Impact factor: 4.534

Review 9.  RAF Kinase Inhibitor Protein in Myeloid Leukemogenesis.

Authors:  Armin Zebisch; Veronica Caraffini; Heinz Sill
Journal:  Int J Mol Sci       Date:  2019-11-16       Impact factor: 5.923

Review 10.  RKIP Pleiotropic Activities in Cancer and Inflammatory Diseases: Role in Immunity.

Authors:  Roni Touboul; Stavroula Baritaki; Apostolos Zaravinos; Benjamin Bonavida
Journal:  Cancers (Basel)       Date:  2021-12-13       Impact factor: 6.639

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.